AZNAstraZenecaRunning, no new patients
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,324 (final count)
- Started
- Oct 11, 2017
- Main results expected
- Aug 27, 2021
- Fully finished
- Dec 31, 2027
- Results posted
- Jun 18, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg
Measured over: From the date of randomization until death due to any cause, assessed up to the data cut-off date (27Aug2021, to a maximum of approximately 46 months).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03298451 · record last updated 2026-10-07 · checked 2026-11-09 15:47 UTC